BioDlink International Co Ltd, formerly TOT BIOPHARM International Co Ltd, is a clinical-stage biopharmaceutical company principally engaged in developing and commercializing oncology drugs and therapies. The Company and its subsidiaries are primarily engaged in research, development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO) business and license-out of self-developed biological drugs in the People’s Republic of China. The Company owns a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The Company has built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and sales and marketing capabilities. The Company mainly conducts its businesses in the domestic market.

© Copyright 1996-20220232 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.